{
    "id": 4150,
    "fullName": "AURKA amp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "AURKA amplification indicates an increased number of copies of the AURKA gene. However, the mechanism causing the increase is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 6790,
        "geneSymbol": "AURKA",
        "terms": [
            "AURKA",
            "AIK",
            "ARK1",
            "AURA",
            "BTAK",
            "PPP1R47",
            "STK15",
            "STK6",
            "STK7"
        ]
    },
    "variant": "amp",
    "createDate": "03/26/2015",
    "updateDate": "07/08/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 1910,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human breast cancer cell lines with AURKA amplification demonstrated sensitivity to Alisertib (MLN8237) (PMID: 22825030).",
            "molecularProfile": {
                "id": 3956,
                "profileName": "AURKA amp"
            },
            "therapy": {
                "id": 626,
                "therapyName": "Alisertib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2391,
                    "pubMedId": 22825030,
                    "title": "Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22825030"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1911,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Zolinza (vorinostat) and Tozasertib (VX-680) synergized to inhibit growth of human breast cancer cell lines harboring AURKA amplification in culture and inhibited tumor growth in AURKA-amplified breast cancer cell line xenograft models (PMID: 22825030).",
            "molecularProfile": {
                "id": 3956,
                "profileName": "AURKA amp"
            },
            "therapy": {
                "id": 2493,
                "therapyName": "Tozasertib + Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2391,
                    "pubMedId": 22825030,
                    "title": "Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22825030"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16057,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Alisertib (MLN8237) treatment of patients with metastatic neuroendocrine prostate cancer (NEPC) harboring AURKA amplification resulted in increased overall survival (p=0.05) compared to those without AURKA amplification (PMID: 30232224; NCT30232224).",
            "molecularProfile": {
                "id": 3956,
                "profileName": "AURKA amp"
            },
            "therapy": {
                "id": 626,
                "therapyName": "Alisertib",
                "synonyms": null
            },
            "indication": {
                "id": 2992,
                "name": "prostate neuroendocrine neoplasm",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14171,
                    "pubMedId": 30232224,
                    "title": "A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30232224"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1250,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alisertib (MLN8237) in combination with Taxotere (docetaxel) inhibited cell viability in gastrointestinal carcinoma cell lines with AURKA amplification and over expression in culture and reduced tumor growth in AURKA-amplified gastrointestinal carcinoma cell line xenograft models (PMID: 22972611).",
            "molecularProfile": {
                "id": 3956,
                "profileName": "AURKA amp"
            },
            "therapy": {
                "id": 1678,
                "therapyName": "Alisertib + Docetaxel",
                "synonyms": null
            },
            "indication": {
                "id": 50922,
                "name": "gastrointestinal carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 71,
                    "pubMedId": 22972611,
                    "title": "The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22972611"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9757,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclincal study, treatment with the combination of Alisertib (MLN8327) and Platinol (cisplatin) resulted in increased apoptosis and decreased growth of TP53-mutant esophageal adenocarcinoma cell lines with AURKA amplfication and overexpression in culture, and increased tumor growth inhibition in xenograft models compared to either agent alone (PMID: 22302096).",
            "molecularProfile": {
                "id": 27055,
                "profileName": "AURKA amp TP53 mut"
            },
            "therapy": {
                "id": 5195,
                "therapyName": "Alisertib + Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 4914,
                "name": "esophagus adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 60,
                    "pubMedId": 22302096,
                    "title": "The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22302096"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16058,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, a patient with metastatic castration-resistant prostate adenocarcinoma with neuroendocrine differentiation harboring AURKA and MYCN amplification, and an MSH6 mutation, remained on Alisertib (MLN8237) therapy for over 3 years with no evidence of disease progression (PMID: 30232224; NCT30232224).",
            "molecularProfile": {
                "id": 31393,
                "profileName": "AURKA amp MSH6 mut MYCN amp"
            },
            "therapy": {
                "id": 626,
                "therapyName": "Alisertib",
                "synonyms": null
            },
            "indication": {
                "id": 2526,
                "name": "prostate adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14171,
                    "pubMedId": 30232224,
                    "title": "A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30232224"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3956,
            "profileName": "AURKA amp",
            "profileTreatmentApproaches": [
                {
                    "id": 10968,
                    "name": "Aurka Inhibitors",
                    "profileName": "AURKA amp"
                },
                {
                    "id": 10967,
                    "name": "AURK Inhibitor (Pan)",
                    "profileName": "AURKA amp"
                }
            ]
        },
        {
            "id": 27055,
            "profileName": "AURKA amp TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31392,
            "profileName": "AURKA amp MYCN amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31393,
            "profileName": "AURKA amp MSH6 mut MYCN amp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}